Feb 4, 2025 8:00 am EST Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Jan 7, 2025 8:00 am EST Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Dec 3, 2024 8:00 am EST FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Nov 7, 2024 4:05 pm EST Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Sep 19, 2024 4:05 pm EDT Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
Sep 9, 2024 7:30 am EDT FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
